Literature DB >> 18663335

Paricalcitol treatment and arterial tone in experimental renal insufficiency.

Emmanouil Karavalakis1, Arttu Eräranta, Tuija I Vehmas, Jenni K Koskela, Peeter Kööbi, Jukka Mustonen, Onni Niemelä, Jaana Rysä, Heikki Ruskoaho, Ilkka Pörsti.   

Abstract

AIM: To examine whether treatment of secondary hyperparathyroidism with paricalcitol provides benefits to arteries in uremic rats.
METHODS: 5/6-nephrectomized rats were treated (NX+Pari) or not treated (NX) with paricalcitol (200 ng/kg, thrice weekly) for 12 weeks. Aortic histology and isolated segments of the main and 2nd-order mesenteric arterial branches were studied.
RESULTS: Creatinine clearance was reduced by 54-61%, plasma phosphate increased 2.1- to 2.5-fold, and blood pressure by 40 mm Hg in both NX groups. PTH increased 13-fold in NX and 5-fold in NX+Pari rats. Calcification in aortic cross-sections increased from 2.1 to 7.1% after paricalcitol. In the large mesenteric artery, vasoconstriction to noradrenaline was reduced in NX+Pari rats. In the large and small arteries, vasorelaxation to acetylcholine was impaired in NX rats and unaffected by paricalcitol. In the small artery, paricalcitol increased nitric oxide synthase inhibition-resistant relaxation to acetylcholine, and maximal relaxation to levcromakalim. The small arteries of NX rats featured increased wall cross-sectional area, while paricalcitol further increased wall thickness and the wall:lumen ratio.
CONCLUSION: Paricalcitol treatment showed both benefits and harmful effects in uremic rats: in the large artery vasoconstriction was reduced but calcification increased, while in the small artery vasorelaxation via potassium channels was moderately improved but hypertrophic remodeling was aggravated. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18663335     DOI: 10.1159/000145464

Source DB:  PubMed          Journal:  Nephron Exp Nephrol        ISSN: 1660-2129


  8 in total

1.  Effect of medial calcification on vascular function in uremia.

Authors:  Roy L Sutliff; Erik R Walp; Alexander M El-Ali; Stacey Elkhatib; Koba A Lomashvili; W Charles O'Neill
Journal:  Am J Physiol Renal Physiol       Date:  2011-04-06

2.  Vitamin d receptor activation mitigates the impact of uremia on endothelial function in the 5/6 nephrectomized rats.

Authors:  J Ruth Wu-Wong; William Noonan; Masaki Nakane; Kristin A Brooks; Jason A Segreti; James S Polakowski; Bryan Cox
Journal:  Int J Endocrinol       Date:  2010-02-10       Impact factor: 3.257

3.  Vitamin d receptor activators and clinical outcomes in chronic kidney disease.

Authors:  Luciana Gravellone; Maria Antonietta Rizzo; Valentina Martina; Nicoletta Mezzina; Anna Regalia; Maurizio Gallieni
Journal:  Int J Nephrol       Date:  2011-05-15

4.  Abnormalities associated with progressive aortic vascular dysfunction in chronic kidney disease.

Authors:  Omar Z Ameer; Rochelle Boyd; Mark Butlin; Alberto P Avolio; Jacqueline K Phillips
Journal:  Front Physiol       Date:  2015-05-19       Impact factor: 4.566

5.  Effect of paricalcitol on renin and albuminuria in non-diabetic stage III-IV chronic kidney disease: a randomized placebo-controlled trial.

Authors:  Thomas Larsen; Frank H Mose; Jesper N Bech; Erling B Pedersen
Journal:  BMC Nephrol       Date:  2013-07-26       Impact factor: 2.388

6.  Unfavorable Reduction in the Ratio of Endothelin B to A Receptors in Experimental 5/6 Nephrectomy and Adenine Models of Chronic Renal Insufficiency.

Authors:  Suvi Törmänen; Päivi Lakkisto; Arttu Eräranta; Peeter Kööbi; Ilkka Tikkanen; Onni Niemelä; Jukka Mustonen; Ilkka Pörsti
Journal:  Int J Mol Sci       Date:  2020-01-31       Impact factor: 5.923

7.  A Novel Vitamin D Receptor Agonist, VS-105, Improves Bone Mineral Density without Affecting Serum Calcium in a Postmenopausal Osteoporosis Rat Model.

Authors:  J Ruth Wu-Wong; Jerry L Wessale; Yung-Wu Chen; Theresa Chen; Maysaa Oubaidin; Phimon Atsawasuwan
Journal:  J Explor Res Pharmacol       Date:  2020-11-06

8.  Ergocalciferol improves endothelial vasodilatory and vasoconstrictor function in an in vivo model of mild uraemia.

Authors:  Gavin Dreyer; Julius Kieswich; Steven Harwood; Amrita Ahluwalia; Muhammad M Yaqoob
Journal:  Biosci Rep       Date:  2019-12-20       Impact factor: 3.840

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.